Recommended

GSK appoints new CEO
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Demand for containment facilities and manufacturing to grow

4
SHARES

The market for containment facilities and containment manufacturing will increase in the future, due to a growing demand for oncology treatments.

containment manufacturing

A recent report has shown that the growing oncology therapy pipeline will have a beneficial impact on containment facilities. The research also shows that the demand for containment manufacturing will increase in the future.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

…the demand for containment manufacturing will increase in the future”

The research was conducted by GlobalData, which studied a total of 1,754 small molecule active pharmaceutical ingredient (API) contract manufacturing facilities. Twenty-nine percent of facilities were found to offer containment capabilities and seven percent offered controlled substance capabilities.  

AMRI, Apeloa and Patheon are highlighted by the report as being among the contract manufacturing organisations (CMOs) with the highest number of containment facilities that are able to handle substances including antibiotics, cytotoxins and steroids.

China was found to have the largest number of small molecule API manufacturing facilities, followed by India and then the US. This is despite the US having 31 percent of small molecule API facilities, compared to China’s 26 percent and 20 percent in India.

Note: Only facility counts for companies engaged in contract manufacturing are included in this figure. Dedicated CMOs only perform contract manufacturing, not both manufacturing and marketing their own products (credit: GlobalData).

Adam Bradbury, PharmSource analyst at GlobalData, said: “The emerging markets of China and India provide much of the small molecule API supply globally as well as lower-cost labour and fewer regulations than in North America… The savings are passed on to the consumer and generics can be sold cheaper in an already competitive environment.”

Bradbury continues: “Controlled substance capabilities and facility requirements can be prohibitively expensive. As such, only the largest CMOs can acquire, construct, and/or maintain a controlled substance facility. Therefore, any reaction in the US involving a reduction in their production will negatively affect the larger CMOs involved.”

Share via
Share via